SecBot SecBot

ADPT

Adaptive Biotechnologies Corp
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. WA· CIK 0001478320 Biotech & Drug Discovery
$25.51 +1.10 (+4.51%)
Oct 23 4:00 PM ET · prev $24.41
Market cap
$3.9B
Mid cap
Consensus
Buy
87% Buy or better · 15 analysts
Median target
🔒 Subscribers only
1 year
+48.1%
from $17.22 · Oct 24
30 days
−13.7%
from $29.57
52-week range
$12.41–29.84
−15% from high · low Mar 27
Avg volume 20D
2.12M
Oct 1 spike 6.02M
Short interest
11.84M
≈7.4% of shares · −12.2%
Days to cover
4.4
at average volume
Insider net
-$5.6M
0 buyers · 3 sellers · since Sep 16
New fund stakes
2
Q2 2026 13F · 1 exit
Filing reports
20
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 4 bearish · 1 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 3/9 ·Next Earnings date, Nov 4, 2026
Strongest BULLISH Adaptive Biotechnologies announced a new consensus definition of cure for multiple myeloma, established by…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $5.6M.

  • InstitutionsBULLISH

    Q2 2026: 35 added (2 new), 17 trimmed or exited. Largest new: Freestone Grove Partners $18.9M, Wasatch Advisors $12.4M.

  • AnalystsBULLISH

    13 of 15 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −12.2% to 11.84M shares. 4.4 days to cover, ≈7.4% of shares.

  • TrendDOWNTREND

    2% below its 50-day average.

Who's buying

13F· Q2 2026
2
new positions
1
exit
$31.3M
in new stakes
FundMoveSharesValue
WELLINGTON MANAGEMENT GROUP LLPADD5,911,366$126.8M
D. E. Shaw & Co., Inc.DOUBLED4,625,859$99.2M
PRICE T ROWE ASSOCIATES INC /MD/ADD2,665,308$57.2M
DRIEHAUS CAPITAL MANAGEMENT LLCADD2,527,703$54.2M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPADD2,524,620$54.2M
Nuveen, LLCADD2,366,155$50.8M
BANK OF AMERICA CORP /DE/ADD1,730,044$37.1M
JANE STREET GROUP, LLCDOUBLED1,590,513$34.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 87% rate it Buy or better
Strong Buy5Buy8Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 13, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Oct 13, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Oct 1, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Sep 29, 2026Goldman Sachs
INITIATE
INITIATEBuy
Sep 22, 2026BTIG
MAINTAIN
MAINTAINBuy
Aug 4, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$5.6M
sold · 3 insiders
DateInsiderTypeValue
Oct 21, 2026
RUBINSTEIN JULIE
President and COO
EXERCISE$144.2K
Oct 21, 2026
RUBINSTEIN JULIE
President and COO
SELL$150.4K
Oct 21, 2026
RUBINSTEIN JULIE
President and COO
SELL$151.5K
Oct 20, 2026
RUBINSTEIN JULIE
President and COO
EXERCISE$144.2K
Oct 20, 2026
RUBINSTEIN JULIE
President and COO
SELL$289.0K
Oct 20, 2026
RUBINSTEIN JULIE
President and COO
SELL$2.5K
Oct 19, 2026
RUBINSTEIN JULIE
President and COO
EXERCISE$144.2K
Oct 19, 2026
RUBINSTEIN JULIE
President and COO
SELL$285.7K

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
11,843,887
shares short
-12.2%
vs prior settlement
4.4
days to cover
≈7.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 Insider
RUBINSTEIN JULIE acquired via exercise 11,881 shares
President and COO @ $12.14 ($144.2K)
Oct 21, 2026 Insider
RUBINSTEIN JULIE sold 5,882 shares
President and COO @ $25.57 ($150.4K)
Oct 21, 2026 Insider
RUBINSTEIN JULIE sold 5,999 shares
President and COO @ $25.25 ($151.5K)
Oct 6, 2026 SEC
Susan Bobulsky, an officer of Adaptive Biotechnologies, filed a Form 144 on October 6, 2026, indicating intent to sell…
144 — Impact 2/10
Oct 6, 2026 SEC
Two senior executives at Adaptive Biotechnologies (Chief People Officer and President/COO) sold a combined ~$390K in…
CLUSTER — Impact 3/10
Sep 25, 2026 Press
Adaptive Biotechnologies announced a new consensus definition of cure for multiple myeloma, established by IMS and…
Impact 6/10
Sep 25, 2026 FDA
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
Adaptive highlights the role of MRD in the new consensus definition of cure in multiple myeloma, pre
Sep 19, 2026 SEC
Two ADPT insiders sold a combined $3.05M in open-market sales over a 7-day window. The vast majority ($3.01M) came…
CLUSTER — Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Sep 25, 2026
FDA
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
Adaptive highlights the role of MRD in the new consensus definition of cure in multiple myeloma, presented at the IMS 23rd Annual Meeting.
Sep 1, 2026
Press release
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims…
Jul 29, 2026
Earnings date
ADPT Q2 2026 Earnings After Market Close — 2026-07-29
Jun 30, 2026
Short interest
Short Interest: ADPT up 49% to 11.4M shares
Settlement 2026-06-30 | Days to cover: 2.23 | ≈7.09% of shares outstanding (est.)
Jun 17, 2026
Press release
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
SEATTLE, June 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today announced the…

SecBot reports

20 filings · 1 press releases · 1 bullish · 5 bearish · 1 mixed · 13 neutral
All ADPT filing & press-release reports (28)